Langerhans cell histiocytosis with central nervous system involvement-complete response to 2-chlorodeoxyadenosine after failure of tyrosine kinase inhibitor therapies with sorafenib and imatinib

Hematological Oncology

Volumn 30, Issue 2, 2012, Pages 101-104

  Baumann, Michael ^a   Cerny, Thomas ^a   Sommacal, Andreas ^a   Koeberle, Dieter ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

2 chloro deoxy adenosine; CNS involvement; Imatinib; Langerhans cell histiocytosis; Sorafenib

Indexed keywords

CD68 ANTIGEN; CLADRIBINE; DESMOPRESSIN; GADOLINIUM; IMATINIB; SORAFENIB; STEROID; TESTOSTERONE; THYROXINE;

ADULT; ARTICLE; BONE MARROW BIOPSY; BRAIN DAMAGE; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; COGNITIVE DEFECT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ELECTRON MICROSCOPY; ERECTILE DYSFUNCTION; HAND FOOT SYNDROME; HISTIOCYTOSIS X; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; IMMUNOHISTOCHEMISTRY; JAW DISEASE; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT RESPONSE; VISUAL DISORDER;

ADULT; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CENTRAL NERVOUS SYSTEM DISEASES; CLADRIBINE; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRIMIDINES;

EID: 84861826086     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.1005     Document Type: Article

References (18)

1. Grois NG, Favara BE, Mostbeck GH, Prayer D. Central nervous system disease in Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998 Apr; 12(2): 287-305.
2. Dhall G, Finlay JL, Dunkel IJ, et al. Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine. Pediatr Blood Cancer 2008 Jan; 50(1): 72-79.
3. Gadner H, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr 2001 May; 138(5): 728-734.
4. Gadner H, Grois N, Potschger U, et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood 2008 Mar 1; 111(5): 2556-2562.
5. Histiocyte Society. Available at: Accessed October 14, 2010.
6. Gotz G, Fichter J. Langerhans'-cell histiocytosis in 58 adults. Eur J Med Res 2004 Nov 29; 9(11): 510-514.
7. Derenzini E, Fina MP, Stefoni V, et al. MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients. Ann Oncol 2010 Jun; 21(6): 1173-1178.
8. Montella L, Insabato L, Palmieri G. Imatinib mesylate for cerebral Langerhans'-cell histiocytosis. N Engl J Med 2004 Sep 2; 351(10): 1034-1035.
9. Utikal J, Ugurel S, Kurzen H, et al. Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses. Arch Dermatol 2007 Jun; 143(6): 736-740.
10. Janku F, Amin HM, Yang D, Garrido-Laguna I, Trent JC, Kurzrock R. Response of histiocytoses to imatinib mesylate: fire to ashes. J Clin Oncol 2010 Nov 1; 28(31): e633-e636.
11. Wagner C, Mohme H, Kromer-Olbrisch T, Stadler R, Goerdt S, Kurzen H. Langerhans cell histiocytosis: treatment failure with imatinib. Arch Dermatol 2009 Aug; 145(8): 949-950.
12. Haroche J, Amoura Z, Charlotte F, et al. Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis. Blood 2008 Jun 1; 111(11): 5413-5415.
13. Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010 Sep 16; 116(11): 1919-1923.
14. Saven A, Burian C. Cladribine activity in adult langerhans-cell histiocytosis. Blood 1999 Jun 15; 93(12): 4125-4130.
15. Bernard F, Thomas C, Bertrand Y, et al. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer 2005 Nov; 41(17): 2682-2689.
16. Stine KC, Saylors RL, Williams LL, Becton DL. 2-Chlorodeoxyadenosine (2-CDA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients. Med Pediatr Oncol 1997 Oct; 29(4): 288-292.
17. Weitzman S, Braier J, Donadieu J, et al. 2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society. Pediatr Blood Cancer 2009 Dec 15; 53(7): 1271-1276.
18. Watts J, Files B. Langerhans cell histiocytosis: central nervous system involvement treated successfully with 2-chlorodeoxyadenosine. Pediatr Hematol Oncol 2001 Apr-May; 18(3): 199-204.